摘要
目的:探讨p53、p16与增殖细胞核抗原（PCNA）在卵巢恶性肿瘤中的表达及临床意义。方法:采用免疫组化LSAB法检测p53、p16、PCNA在各种卵巢组织中的表达,并与多项临床参数进行分析。结果:恶性肿瘤中p53、PCNA的表达率明显高于卵巢正常组织、良性肿瘤及交界性肿瘤,p16的表达率则低于对照组（P<0.05）。p53、p16的表达与肿瘤的组织学分级、浸润、转移有不同程度的相关性（P<0.05）,而PCNA的表达则未见明显相关性（P>0.05）;3种指标均与患者预后有关,但与临床分期未见明显相关性（P>0.05）;p16、PCNA的表达均与p53的表达相关,但在前2者之间未见明显相关性（P>0.05）。结论:检测p53、p16、PCNA的表达对于辅助诊断卵巢恶性肿瘤、判断患者预后,具有重要价值。
ve: To determine expressions of p53,p16 and proliferating cell nuclear antigen (PCNA) in ovarian malignant tumors and the clinical sigificance. Methods: Immunohis-tochemical LSAB assay was adopted to examine the expressions of p53,p16 and PCNA in various o-varian tissues in order to analyse with clinical parameters. Results: The expressions of p53, PCNA in ovarian malignant tumors were significantly higher than those in normal ovarian tissues, benign tu-mors and borderline tumors,but the expression of p16 was lower than that in the control groups (P < 0.05). The expressions of p53 and p16 were significantly related with the histologic grade, inva-sion and metastasis ( P < 0.05 ) , but PCNA was not. The three indexes were related with patient' s prognosis,but not with clinical staging (P > 0.05) .The expressions of p16 and PCNA were related with p53, but the former two were not (P > 0.05) . Conclusion: Expressions of p53, p16 and PCNA have very important value in assisted diagnoses for ovarian malignant tumors and assessing prognoses of patients.
出处
《现代妇产科进展》
CSCD
2002年第3期185-187,共3页
Progress in Obstetrics and Gynecology
